Cash Flow Statement

Acquisitions Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Depreciation Expense EBIAT Leases Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Purple Biotech (PPBT) Long-Term Debt Issuances (2016)

Purple Biotech has reported Long-Term Debt Issuances over the past 1 years, most recently at $129800.0 for Q4 2016.

Quarterly Long-Term Debt Issuances changed N/A to $129800.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $129800.0 through Dec 2016, changed N/A year-over-year, with the annual reading at -$16000.0 for FY2017, 112.33% down from the prior year.
Long-Term Debt Issuances was $129800.0 for Q4 2016 at Purple Biotech.
Over five years, Long-Term Debt Issuances peaked at $129800.0 in Q4 2016 and troughed at $129800.0 in Q4 2016.